Rein Therapeutics Inc.
RNTX
$1.64
-$0.16-8.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.72% | -53.56% | 20.15% | 179.87% | 71.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.15% | -20.61% | 207.08% | 334.57% | 80.62% |
| Operating Income | 22.15% | 20.61% | -207.08% | -334.57% | -80.62% |
| Income Before Tax | 22.66% | -479.44% | -220.03% | -400.39% | -48.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.66% | -458.40% | -220.03% | -400.39% | -48.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.66% | -458.40% | -220.03% | -400.39% | -48.84% |
| EBIT | 22.15% | 20.61% | -207.08% | -334.57% | -80.62% |
| EBITDA | 21.73% | 20.04% | -208.96% | -336.90% | -81.09% |
| EPS Basic | 70.70% | -22.77% | 32.91% | -14.13% | 18.59% |
| Normalized Basic EPS | 70.70% | 83.50% | 32.68% | -8.76% | -3.56% |
| EPS Diluted | 70.70% | -22.77% | 32.91% | -14.13% | 18.59% |
| Normalized Diluted EPS | 70.70% | 83.50% | 32.68% | -8.76% | -3.56% |
| Average Basic Shares Outstanding | 163.99% | 354.83% | 377.03% | 338.46% | 82.81% |
| Average Diluted Shares Outstanding | 163.99% | 354.83% | 377.03% | 338.46% | 82.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |